Poolbeg Pharma plc – Decision to grant European Patent received for POLB 001 in cancer immunotherapy-induced CRS
Major milestone will provide IP protection in key European markets, strengthening global patent portfolio
16 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that it has received formal notification of the decision to grant for its POLB 001 cancer immunotherapy-induced Cytokine Release Syndrome (“CRS”) patent application from the European Patent Office (“EPO”).
